According to preclinical studies across multiple animal models, the NAV technology, and in particular NAV rAAV8 vector, targets the photoreceptor layer to preserve vision using gene delivery approaches.
The company holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV technology and related applications.
Regenx president and CEO Kenneth Mills said they are pleased to have received this funding and support from NEI and recognize the critical importance of accelerating early stage development into meaningful treatments for inherited and acquired retinal diseases.